Houman is a renowned clinician scientist and highly successful entrepreneur. As co-founder of Weatherden, he provides strategic direction to the company’s management team as it continues to evolve into one of the biotech sector’s preferred clinical consulting partners.
He is a Managing Partner at SV Health Investors and was previously Vice President and Head of Clinical Sciences at UCB. With specific interests in immune-oncology, metabolism and genetics, he co-founded Heart Metabolics which successfully repositioned perhexiline as a treatment for hypertrophic cardiomyopathy and heart failure, and the services company Cardiac Report. He has founded six companies since joining SV; Sitryx, Enara Bio, Zarodex, TrexBio, Alchemab and Cellinta.
Houman completed his medical training at the Radcliffe Department of Medicine, University of Oxford where he was appointed as an Honorary Consultant Cardiologist and remains a Visiting Professor and Head of Experimental Therapeutics. During his career, Houman has authored over 70 publications and received dozens of awards for his work.